Clinical Trial Update: Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating trametinib, a MEK inhibitor, as a targeted treatment for Langerhans Cell Histiocytosis and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: Cook Children's Health Care System | Conditions: Langerhans Cell Histiocytosis | Phase 2 | Status: RECRUITING